The risk of developing these severe side effects is very small, but it is important that patients and healthcare professionals are aware and alert to the associated symptoms. An estimated 1.6 million UK adults used GLP-1s such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) to lose weight between early 2024 and early 2025, with an additional 3.3 million interested in using weight loss drugs during 2026
Alcohol Use Disorder: A study published in Translational Psychiatry found that GLP-1 receptor agonists reduced alcohol consumption in animal models of alcohol use disorder
This article examines the evidence for natural compounds that may influence GLP-1 and GIP activity, their safety considerations, and when to consult your GP about metabolic health concerns
They make it clear that these supplements are not a quick fix
Retrieved from Zhao, Z., Tang, Y., Hu, Y., et al
(no photo available) $559 KT-714 Corticotropin Releasing Hormone Binding Protein (CRHBP) ELISA Kit, Human For quantitative detection in human samples
